Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids | Organoid wiki

Source

PDF: raw/sources/dekkers_2021_long-term_culture_genetic_manipulation_and.pdf
Article: https://www.nature.com/articles/s41596-020-00474-1
Status: deep ingested on 2026-04-08
Organ focus: breast
Protocol focus: breast organoid derivation, engineering, and xenotransplantation

Starting material: primary healthy or disease tissue, tumor material, and related patient samples
Protocol type: engineering, imaging, or perturbation protocol layered onto organoid culture
Aim: breast organoid derivation, engineering, and xenotransplantation
Core readouts: engraftment, repair, or host-integration readouts in vivo

This paper is best understood as an engineering, imaging, or perturbation protocol layered onto organoid culture for breast organoid derivation, engineering, and xenotransplantation.
Its main distinctive contribution in this corpus is that it extends breast organoids into long-term culture, genetic manipulation, and xenotransplantation.
Within this collection, it belongs to the engineering and readout-expansion branch of organoid protocol work.
Paper framing: Organoid technology has revolutionized the study of human organ development, disease and therapy response tailored to the individual. Although detailed protocols are available for the generation and long-term propagation of human organoids from various organs, such methods are lacking for breast tissue.

Defines a workflow centered on breast organoid derivation, engineering, and xenotransplantation.
Its distinctive focus in practice is the way it extends breast organoids into long-term culture, genetic manipulation, and xenotransplantation.
Adds a leverage layer such as imaging, editing, or screening that turns organoids into more mechanistic systems.

Adds a reusable perturbation or imaging layer that increases experimental leverage.
Makes organoids more compatible with mechanistic and platform-style studies.

Usually assumes that the baseline organoid system is already robust before engineering begins.
Technical failure modes may come from delivery, imaging, or screen design rather than from the organoid biology itself.

Specific role in this corpus: Bridges stable patient-derived organoid culture with intervention and in vivo follow-up.
This paper broadens the collection's coverage of breast organoid work.
It matters because many practical organoid projects stall at the perturbation or readout stage rather than at derivation.

Which engineering or readout step is most likely to fail before the biology is interpretable?
How should this workflow be standardized across cell lines, batches, or perturbation sets?

These parsed files are helper artifacts. Treat the original raw PDF as the source of truth.